Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Ranitidine
Cat. No.:
OB0225LY-0112
Appearance:
Viscous
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Ranitidine is an H2 receptor antagonist used primarily to reduce gastric acid secretion.
Synonym:
HSDB 3925; Ranitidin; 66357-35-5
CAS No.:
66357-35-5
Formula:
C13H22N4O3S
Formula Weight:
314.4
Specification
Relative Density:
1.03 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Ranitidine can be used in the study of gastric ulcers, gastroesophageal reflux disease and other conditions caused by excess stomach acid.
Library Information
Targets:
Histamine receptor; P450; Antibacterial
Receptors:
H2 receptor
Pathways:
GPCR/G protein; Metabolism; Immunology/Inflammation; Neuronal signaling; Microbiology/Virology
Plate Number:
AOCL-2
Plate Location:
d5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 174.94 mM
